Who is sponsoring NCT06138210?

NCT06138210 is sponsored by Xuanwu Hospital, Beijing.

What drugs are being tested in NCT06138210?

Interventions in NCT06138210: exosomes derived from human induced pluripotent stem cell for injection, a placebo of exosomes derived from human induced pluripotent stem cell for injection.

What condition does NCT06138210 study?

NCT06138210 studies Acute Ischemic Stroke.

Is NCT06138210 still recruiting?

NCT06138210 is currently recruiting now. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT06138210: ExoCURE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of GD-iExo-003 in Acute Ischemic Stroke

Recruiting now Phase 1, PHASE2 Last updated 4 December 2025

What this trial tests

Phase 1, PHASE2 trial testing exosomes derived from human induced pluripotent stem cell for injection in Acute Ischemic Stroke in 29 participants. Currently enrolling.

Timeline

5 June 2024

Primary endpoint
30 March 2026

30 March 2026

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	29
Start date	5 June 2024
Primary completion	30 March 2026
Estimated completion	30 March 2026
Sites	1 location across China

Drugs / interventions tested

exosomes derived from human induced pluripotent stem cell for injection — full drug profile →
a placebo of exosomes derived from human induced pluripotent stem cell for injection — full drug profile →

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →

Sponsor

Xuanwu Hospital, Beijing

Who can join

Adults 18 to 70, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. The objective of this study is evaluating safety and preliminary efficacy of intravenous exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic stroke.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding the Pathophysiology of Ischemic Stroke: The Basis of Current Therapies and Opportunity for New Ones.
Salaudeen MA, Bello N, Danraka RN, Ammani ML. · · 2024 · cited 89× · PMID 38540725 · DOI 10.3390/biom14030305
Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine.
Sharma A, Yadav A, Nandy A, Ghatak S. · · 2024 · cited 40× · PMID 38931833 · DOI 10.3390/pharmaceutics16060709
Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies.
Mehdizadeh S, Mamaghani M, Hassanikia S, Pilehvar Y, et al · · 2025 · cited 34× · PMID 40319325 · DOI 10.1186/s12951-025-03352-8
Emerging Role of Extracellular Vesicles as Biomarkers in Neurodegenerative Diseases and Their Clinical and Therapeutic Potential in Central Nervous System Pathologies.
Malaguarnera M, Cabrera-Pastor A. · · 2024 · cited 30× · PMID 39337560 · DOI 10.3390/ijms251810068
The Landscape of Exosomes Biogenesis to Clinical Applications.
Al-Madhagi H. · · 2024 · cited 28× · PMID 38681093 · DOI 10.2147/ijn.s463296
Extracellular Vesicles Maintain Blood-Brain Barrier Integrity by the Suppression of Caveolin-1/CD147/VEGFR2/MMP Pathway After Ischemic Stroke.
Li Y, Chen J, Quan X, Chen Y, et al · · 2024 · cited 25× · PMID 38371456 · DOI 10.2147/ijn.s444009
Advancing stroke therapy: innovative approaches with stem cell-derived extracellular vesicles.
Song J, Zhou D, Cui L, Wu C, et al · · 2024 · cited 24× · PMID 39039539 · DOI 10.1186/s12964-024-01752-1
Comparative analysis of regulations and studies on stem cell therapies: focusing on induced pluripotent stem cell (iPSC)-based treatments.
Song SJ, Nam Y, Rim YA, Ju JH, et al · · 2024 · cited 18× · PMID 39574212 · DOI 10.1186/s13287-024-04065-9

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06138210 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06138210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing